Science Links Japan | Problems in Clinical Tests: What Can Be Done Now and What Should Be Done. Current Issues and Perspectives in Japan Clinical Oncology Group.

Problems in Clinical Tests: What Can Be Done Now and What Should Be Done. Current Issues and Perspectives in Japan Clinical Oncology Group.

Accession number;99A0225245

Title;Problems in Clinical Tests: What Can Be Done Now and What Should Be Done. Current Issues and Perspectives in Japan Clinical Oncology Group.

Author; FUKUDA HARUHIKO (National Cancer Center Res. Inst.) NIIMI MIYUKI (National Cancer Center Res. Inst.)

Journal Title;Japanese Journal of Cancer and Chemotherapy

Journal Code:Z0938A

ISSN:0385-0684

VOL.26;NO.2;PAGE.204-211(1999)

Figure&Table&Reference;FIG.4, REF.3

Pub. Country;Japan

Language;Japanese

Abstract;Clinical trials can be classified either as "sponsored trials (sponsored by industries)" or "non-sponsored trials (funded by government etc.)". The former is for the application of the commercialization/import of new drugs by the government, and the latter basically seeks to establish and improve the "State of the Art" of medical treatments/prevention in certain disease fields. We present an overview of the Japan Clinical Oncology Group(JCOG), which is a cooperative group funded by government for conducting non-sponsored cancer clinical trials, and the fundamental procedures managed by our JCOG Data Center. The problems and difficulties concerning data management in our trials, our roles and limitations as a non-commercial data coordinating center, future perspectives and issues on local data management are also discussed. (author abst.)

Related Articles;